Atossa Therapeutics (ATOS) Amortization of Deferred Charges (2015 - 2018)
Atossa Therapeutics (ATOS) posted quarterly Amortization of Deferred Charges of $19853.0 for Q3 2018, little changed year-over-year from $19853.0 in Q3 2017, and little changed quarter-over-quarter from $19851.0 in Q2 2018.
Atossa Therapeutics (ATOS) Amortization of Deferred Charges (2015 - 2018) Analysis & Trends
Atossa Therapeutics (ATOS) has reported Amortization of Deferred Charges for 3 consecutive years, with $19853.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Amortization of Deferred Charges changed 0.0% year-over-year to $19853.0; the TTM figure through Sep 2018 stood at $79408.0 (up 2835.6% YoY), while the FY2017 annual figure was $79410.0, up 85.26% from the prior year.
- Amortization of Deferred Charges held at $19853.0 in Q3 2018 per ATOS's latest filing, from $19851.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $351961.0 in Q1 2015 and bottomed at -$37000.0 in Q4 2015.
- Historically, Amortization of Deferred Charges has averaged $52758.2 across 3 years, with a median of $19852.0 in 2017.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 0.0% in 2018 and fell as far as 0.0% in 2018.
- Atossa Therapeutics' Amortization of Deferred Charges stood at -$37000.0 in 2015, then surged by 153.65% to $19852.0 in 2017, then advanced by 0.01% to $19853.0 in 2018.
- Business Quant data shows ATOS's Amortization of Deferred Charges at $19853.0 in Q3 2018, $19851.0 in Q2 2018, and $19852.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atossa Therapeutics | 22.63 Mn | 22.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 19,853.00 |
| Sep 30, 2018 | 19,853.00 |
| Jun 30, 2018 | 19,851.00 |
| Jun 30, 2018 | 19,851.00 |
| Mar 31, 2018 | 19,852.00 |
| Mar 31, 2018 | 19,852.00 |
| Dec 31, 2017 | 19,852.00 |
| Dec 31, 2017 | 19,852.00 |
| Sep 30, 2017 | 19,853.00 |
| Sep 30, 2017 | 19,853.00 |
| Mar 31, 2017 | 19,852.00 |
| Mar 31, 2017 | 19,852.00 |
| Dec 31, 2015 | -37,000.00 |
| Dec 31, 2015 | -37,000.00 |
| Jun 30, 2015 | 40,750.00 |
| Jun 30, 2015 | 40,750.00 |
| Mar 31, 2015 | 351,961.00 |
| Mar 31, 2015 | 351,961.00 |